期刊文献+

宝肾方对糖尿病大鼠肾组织CTGF和MMP-9的影响 被引量:4

Effects of Shenbao recipe on expressions of CTGF and MMP-9 in diabetic nephropathy rats
原文传递
导出
摘要 目的:探讨宝肾方对糖尿病大鼠的治疗作用及其对肾组织结缔组织生长因子(CTGF)和基质金属蛋白酶-9(MMP-9)表达的影响。方法:以链脲佐菌素(STZ)诱导建立糖尿病大鼠模型。随机分为对照组(C组)、糖尿病组(D组)和糖尿病宝肾方治疗组(DB组)。给药8周后检测各组生化指标,观察肾组织病理形态学改变,采用免疫组化方法分析肾组织CT-GF和MMP-9蛋白的表达情况。结果:和对照组相比,糖尿病组肾组织CTGF蛋白表达明显升高[(0.234±0.009)vs(0.146±0.007),P(0.01],而MMP-9蛋白表达明显降低[(0.146±0.006)vs(0.236±0.007),P(0.01],肾脏肥大指数、24 h尿蛋白、血糖、胆固醇、血肌酐明显升高(P(0.01);和糖尿病组相比,宝肾方治疗组肾组织CTGF蛋白表达降低[(0.194±0.008)vs(0.234±0.009),P(0.01],而MMP-9蛋白表达升高[(0.175±0.007)vs(0.146±0.006),P(0.01],肾脏肥大指数降低(P(0.05),24 h尿蛋白、胆固醇、血肌酐降低(P(0.01)。结论:宝肾方对糖尿病大鼠肾脏具有保护作用,其机制可能与影响肾组织CTGF和MMP-9的表达有关。 Objective: To investigate the effects of Shenbao recipe on expressions of CTGF and MMP-9 in the kidney of diabetic rats.Method: Wistar rats were randomized divided into control group(group C),diabetic rat group(group D) and Bao′shen recipe treatment group(group DB).Streptozotocin(STZ) was injected through abdominal cavity to make models of diabetic rats.Administration for 8 weeks,renal function and pathological changes of rats′ renal tissue were observed,protein expression of CTGF and MMP-9 in renal tissue was investigated by immunohistochemistry analysis.Result: Compared with group C,expressions of CTGF in renal tissue of group D were higher [(0.234±0.009) vs(0.146±0.007),P0.01],while the expressions of MMP-9 were lower [(0.146±0.006) vs(0.236±0.007),P0.01].Kidney hypertrophy index,24-hour urinary protein,blood glucose,cholesterol and serum creatinine were increased significantly in the group D.The level of MMP-9 expression was increased [(0.175±0.007) vs(0.146±0.006),P0.01],while the level of CTGF expression was reduced [(0.194±0.008) vs(0.234±0.009),P0.01] by using Shenbao recipe.In group DB,all index including kidney hypertrophy index,24-hour urinary protein,cholesterol and serum creatinine were obviously lower than diabetic rat group.Conclusion: Shenbao recipe can depress the expressions of CTGF and increase the expressions of MMP-9 in the kidney of diabetic rats,which can be served as a protective effect to prevent progress of diabetic nephropathy.
出处 《中国中药杂志》 CAS CSCD 北大核心 2010年第14期1874-1877,共4页 China Journal of Chinese Materia Medica
基金 甘肃省中医药管理局基金项目
关键词 中药 糖尿病肾病 结缔组织生长因子 基质金属蛋白酶-9 traditional Chinese drug diabetic nephropathy connective tissue growth factor matrix metalloproteinase-9
  • 相关文献

参考文献6

二级参考文献27

  • 1胡衍园,文秀英,石珺,许明望.五龙克糖口服液对2型糖尿病大鼠胰岛β细胞的保护作用[J].中国中西医结合杂志,2003,23(S1):123-126. 被引量:4
  • 2刘玉莲,杨丛忠.黄芪药理作用概述[J].中国药业,2004,13(10):79-79. 被引量:85
  • 3杨俊伟,黎磊石,张真.大黄治疗糖尿病肾病的实验研究[J].中华内分泌代谢杂志,1993,9(4):222-224. 被引量:105
  • 4陈清江,杨丽,王辉,刘章锁.黄芪对人肾间质成纤维细胞增殖和转化生长因子-β1表达的影响[J].郑州大学学报(医学版),2005,40(5):871-873. 被引量:59
  • 5赵三妹 夏人仪.动脉平滑肌细胞的培养方法及其应用[J].中华病理学杂志,1987,16:260-260.
  • 6徐国钧.生药学[M].北京:人民卫生出版社,1988.422-424.
  • 7Pei-Feng Li, Rainer Dietz,Rudiger von Harsdorf. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation, 1997,96:3602.
  • 8Yoon K C, Jayoung K, Sijoong K, et al. Phosphatidylinositol 3-kinase stimulates muscle differentiation by activating p38 mitogen-activated protein kinase. Biochem Biophys Res Commun, 2000, 276(2):502.
  • 9Raingeaud J S, Gupta J S, Rogers M, et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem, 1995,270:7420.
  • 10Christian V, Vbaldo S, Heidemarie K, et al. Differential activation of mitogen-activated protein kinase in smooth muscle cells by angiotensin Ⅱ. Arterioscler Thromb Vasc Biol, 2000, 20:940.

共引文献119

同被引文献41

  • 1绪广林,余书勤,龚祝南,张双全.西红花苷对大鼠实验性高脂血症的影响及其机制研究[J].中国中药杂志,2005,30(5):369-372. 被引量:19
  • 2Perico N, Codreanu I, Schieppati A, et al. Prevention of pro- gression and remission / regression strategies for chronic kidney diseases: can we do better now than five year ago? [J]. Kidney Int Suppl, 2005(98) :S22-S24.
  • 3Atkins R C. The changing patterns of chronic kidney disease: the need to development strategies for prevention relevant to different regions and countries [J]. Kidney lnt Suppl, 2005 (98): S83-S85.
  • 4National Kidney Foundation. K/DOQ. Clinical practice guide- lines for chronic kidney disease: evaluation, classification, and stratification [J]. Am J Kidney Dis, 2002,39 (2 suppl 1): S264-S266.
  • 5Farris A B, Colvin R B. Renal interstitial fibrosis: mecha-nisms and evaluation[J]. Curr Opin Nephrol Hypertens,2012,21(3): 289-300.
  • 6Lambers Heerspink H J, de Zeeuw D. Novel drugs and in-tervention strategies for the treatment of chronic kidneydisease[J]. Br J Clin Pharmacol, 2013, 76(4): 536-550.
  • 7Altinoz E, Oner Z, Elbe H, et al. Protective effects of saf-fron (its active constituent, crocin) on nephropathy instreptozotocin-induced diabetic rats[J]. Hum Exp Toxicol,2015, 34(2): 127-134.
  • 8Sommer M, Funfstuck R. Pathogenesis of interstitialkidney fibrosis: studies in the rat model of unilateral ure-teral obstruction[J]. Medizinische Klinik, 1997, 92(10):582-588.
  • 9Ucero A C, Benito-Martin A, Izquierdo M C, et al. Uni-lateral ureteral obstruction: beyond obstruction[J]. IntUrol Nephrol, 2014, 46(4): 765-776.
  • 10Zhou T B, Qin Y H, Lei F Y, et al. Association of pro-hibitin' 1 and 2 with oxidative stress in rats with renalinterstitial fibrosis[J]+ Mol Biol Rep, 2014, 41(5): 3033-3043.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部